EUVIMEDEUVIMED entdecken
Crossref

Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients With Breast Cancer

Shawna L Kuhlers, Emily Kathol, David Hartnett-Quach, Jairam Krishnamurthy, Kealy Marth

Clinical Breast Cancer · 2025

DOI: 10.1016/j.clbc.2024.11.009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Shawna L Kuhlers und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nebraska Medicine, Department of Pharmacy, Pharmacy Residency Program, Omaha, NE. Electronic address: skuhlers@uwhealth.org. Hauptthemen laut MEDLINE: Dexamethasone, Paclitaxel, Breast Neoplasms, Drug Hypersensitivity. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Paclitaxel has a boxed warning for causing severe hypersensitivity reactions, however, the majority (95%) of these reactions occur during the first or second infusion. Corticosteroids can reduce the incidence of paclitaxel hypersensitivity reactions from 30% to around 1%-3% but are not without adverse effects. Current practice at our institution is to prescribe dexamethasone 20 mg to be given orally 12 and 6 hours prior to paclitaxel infusion, however, some medical oncology providers have elected to decrease or omit dexamethasone premedication. METHODS: This retrospective study analyzed dexamethasone dose adjustment(s) prior to paclitaxel and the incidence of hypersensitivity reactions. Patients were included if they were ≥19 years, had breast cancer, received ≥3 doses of paclitaxel as part of (neo)adjuvant therapy, and received reduced or omitted oral dexamethasone prior to paclitaxel between January 1, 2015, and July 31, 2023. The primary outcome was incidence of rescue medication administration in those with reduced or omitted premedication dexamethasone. Secondary outcomes included dexamethasone prescribing practices and the incidence of corticosteroid-associated insomnia and hyperglycemia. RESULTS: The analysis included 306 infusions (corticosteroid reduction: 283; omission: 23). A hypersensitivity reaction requiring the administration of rescue medications occurred in 5 infusions in the reduction group (1.6%) and 0 infusions in the omission group, leading to a 1.6% overall incidence of infusions requiring the administration of rescue medications. CONCLUSION: In conclusion, decreasing home dexamethasone prior to paclitaxel infusions did not increase the incidence of hypersensitivity reactions compared to rates reported in the literature.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasonePaclitaxelBreast NeoplasmsDrug HypersensitivityDrug TaperingHumansFemaleRetrospective StudiesMiddle AgedAgedAdultIncidenceInfusions, Intravenous

Stichwörter der Autor:innen

CorticosteroidsHypersensitivity reactionsPremedicationPrescribing practicesTaxane chemotherapy

Substanzen

DexamethasonePaclitaxel

Autor:innen und Institutionen

  • Nebraska Medicine, Department of Pharmacy, Pharmacy Residency Program, Omaha, NE. Electronic address: skuhlers@uwhealth.org.
  • Nebraska Medicine, Department of Pharmacy Practice and Science, Omaha, NE.
  • Department of Oncology/Hematology, University of Nebraska Medical Center, Omaha, NE.

Zitieren

APA

Kuhlers, S. L., Kathol, E., Hartnett-Quach, D., Krishnamurthy, J., & Marth, K. (2025). Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients With Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.11.009

Vancouver

Kuhlers SL, Kathol E, Hartnett-Quach D, Krishnamurthy J, Marth K. Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients With Breast Cancer. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.11.009

BibTeX
@article{Kuhlers2025,
  author = {Kuhlers, Shawna L and Kathol, Emily and Hartnett-Quach, David and Krishnamurthy, Jairam and Marth, Kealy},
  title = {Assessing Outcomes of Tapering 12-Hour and 6-Hour Dexamethasone Prior to Paclitaxel Infusions in Patients With Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2025},
  doi = {10.1016/j.clbc.2024.11.009}
}
Kostenlos starten →